Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Pennsylvania Zepbound Prior Auth Policy |…
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Medication prior authorization for Zepbound

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a medication prior authorization form used by Highmark Pennsylvania to request approval for Zepbound (weight management medication). It governs providers submitting authorization requests and members being considered for Zepbound therapy.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization for Zepbound
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the completed form and all clinical documentation by fax to 1-866-240-8123 or by mail to Highmark SPECARE at 120 Fifth Avenue, Pittsburgh, PA 15222; one form per medication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Faxsubmission channel
    Mailmail option

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Diet, activity, sleeprequired docs
    One per medform rule

    Coverage Criteria for Zepbound Prior Authorization

    Initial authorization documentation requirements

    Coverage requires submission of completed form with supporting clinical documentation demonstrating lifestyle modification efforts, relevant comorbidities, and baseline measurements.

    Documentation and clinical verification: Provider must document (1) participation in a lifestyle modification program that encourages reduced calorie diet and increased physical activity and duration in months, with attached documentation from acceptable sources (diet documentation such as provider chart notes, dietary logs, recurring program receipts or nutrition counseling; and physical activity documentation such as chart notes, gym receipts, wearable device reports, or trainer receipts); (2) baseline height, weight, and body mass index (BMI) prior to initiating Zepbound with attached chart documentation; (3) prior weight-loss medication trials and dates if applicable; (4) if diagnosis of prediabetes is present, confirmatory test within the past 6 months (A1c 5.7%–6.4% or FPG 100–125 mg/dL or OGTT 140–199 mg/dL) with attached results; (5) for obstructive sleep apnea, baseline AHI and RDI from polysomnography or recording time without positive airway pressure or oral appliance and, if performed, baseline AHI/RDI after optimization of guideline-directed care, with attached sleep study reports; and (6) documentation of weight-related comorbidities as applicable.see documentation nodes

    All supporting documentation types are listed on the form

    Initial therapy requirements

    Initial therapy requires demonstration of lifestyle modification efforts and baseline measures.

    Initial therapy: Provide documentation of participation in a lifestyle modification program (reduced calorie diet and increased physical activity) with duration in months and attach supporting documentation (examples: provider chart notes, dietary logs, recurring program receipts, nutrition counseling records, wearable device reports); provide baseline height, weight, and BMI (before therapy with Zepbound or any other weight loss medication) with supporting chart documentation; list prior weight-loss medications tried and failed with dates if applicable.N/A

    Acceptable documentation types are listed on the form

    Continuation and Monitoring Requirements

    Continuation/Monitoring

    Continuation or ongoing therapy requires current on-therapy measures and documentation.

    On-therapy monitoring: If member is currently on a weight loss medication, provide current (on-therapy) height, weight, and BMI and the duration on therapy; attach chart notes to support measurements and dates; for obstructive sleep apnea, provide current (after therapy) AHI and RDI with use of positive airway pressure or oral appliance as applicable and attach device reports or sleep study documentation; indicate whether continued Zepbound therapy is required to maintain improvement.N/A

    Attach chart notes or device reports

    Continuation for established therapy

    For established use (including obstructive sleep apnea) where Zepbound has already been started, provide duration on therapy and current objective measurements to justify continuation.

    Established therapy continuation: Specify how long the member has been on Zepbound and provide current AHI/RDI and positive airway pressure device reports or sleep study documentation if treating obstructive sleep apnea; indicate whether additional therapy with Zepbound is required to maintain a decrease in AHI/RDI; attach supporting documentation demonstrating benefit or need for continuation.

    Step Therapy and Prior Medication Trials

    Previous weight‑loss medicationDates of therapy (start — end)Baseline height/weight/BMI documented
    Contrave (naltrexone/bupropion)
    Wegovy (semaglutide)
    Qsymia (phentermine/topiramate)
    Xenical (orlistat)
    Saxenda (liraglutide)
    Previous Zepbound
    Other (specify)

    Relevant Clinical Thresholds and Adherence Definitions

    Prediabetes lab thresholds — numeric ranges
    A1c (Hemoglobin A1c)5.7% to 6.4%
    Fasting plasma glucose (FPG)100 to 125 mg/dL
    Oral glucose tolerance test (OGTT) 2-hour140 to 199 mg/dL
    Positive airway pressure adherence
    PAP device adherence definitionDevice used ≥70% of nights for ≥4 hours per night, for ≥2 months
    Documentation requiredAttach device report demonstrating nightly usage and hours per night
    Applicability note

    Submission Instructions and Provider Requirements

    Denial Risk

    Submission and payment risk

    Fax the completed form and all clinical documentation to 1-866-240-8123 or mail to: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222. Submit a separate form for each medication. Print, type, or write legibly in blue or black ink. Complete ALL information on the form. The prescribing physician (PCP or Specialist) should, in most cases, complete the form. Provide the physician address for notification.

    • Submit a separate form for each medication
    • Fax: 1-866-240-8123
    • Mail: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222
    • Complete ALL information on the form
    • Prescribing physician should complete the form
    • Provide physician address for notification
    Documentation Required

    Key Definitions

    Lifestyle modification program — definition and examples
    DefinitionA lifestyle modification program encourages a reduced-calorie diet and increased physical activity; documentation of participation and duration (months) is required
    Examples — commercial programsNoom, Weight Watchers (WW), Vida, Lark, Signos, Wondr, Livongo, Omada, Newtopia, Virta
    Examples — health system programsPlan-sponsored coaching programs such as My Weight Management Journey or Penn State Health obesity medicine institute
    Acceptable diet documentationProvider chart notes, recurring subscription receipts, dietary logs, or recurring nutrition counseling receipts (monthly)
    Acceptable activity documentationProvider chart notes specifying type, duration, and frequency of physical activity or program participation records

    Background

    This prior authorization form supports requests for Zepbound, a GLP-1 receptor agonist indicated for weight management used in conjunction with lifestyle interventions. The form is designed to document the clinical rationale for therapy by capturing the member's participation in a structured lifestyle modification program (reduced calorie diet and increased physical activity), duration of participation, and objective baseline anthropometrics (height, weight, BMI) prior to initiating Zepbound.

    The form also collects information about weight-related comorbidities (for example, prediabetes, type 2 diabetes, and atherosclerotic cardiovascular disease), prior weight-loss medication trials with dates, and, when applicable, detailed evaluation and management of obstructive sleep apnea including baseline and post-optimization AHI/RDI and documentation of positive airway pressure or oral appliance adherence. Submission instructions clarify that one completed form is required per medication and that the completed form and supporting clinical documentation must be faxed or mailed to Highmark for prior authorization review.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization for Zepbound
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the completed form and all clinical documentation by fax to 1-866-240-8123 or by mail to Highmark SPECARE at 120 Fifth Avenue, Pittsburgh, PA 15222; one form per medication.
    SourceLink
    On This Page
    Coverage Criteria for Zepbound Prior AuthorizationContinuation and Monitoring RequirementsStep Therapy and Prior Medication TrialsRelevant Clinical Thresholds and Adherence DefinitionsSubmission Instructions and Provider RequirementsKey DefinitionsBackground
    N/A

    Attach supporting documentation

    Ongoing benefit or adherence: Provide evidence of clinical benefit or adherence while on therapy (for example, objective improvement in AHI/RDI, continued participation in lifestyle modification program, or documentation of weight change) and duration on therapy; attach chart notes or device reports as applicable.N/A

    Documentation should be current and attached

    Question may only apply for certain plan types; confirm plan-specific requirements

    Required supporting documentation

    Attach documentation demonstrating the member's participation in a lifestyle modification program that includes both reduced calorie diet and increased physical activity. One item from each category (Diet and Physical Activity) is required.

    • Diet — provider chart notes detailing dietary adjustments and/or calorie deficit
    • Diet — recurring receipts for a lifestyle program subscription (for example, Noom, Weight Watchers, Vida, Lark, Signos, Wondr, Livongo, Omada, Newtopia, Virta, employer/plan-sponsored programs) provided monthly
    • Diet — dietary log maintained by member detailing diet/calorie deficit
    • Diet — recurring appointments for private nutritional counseling or medical nutrition therapy (receipt or chart documentation monthly)
    • Physical Activity — provider chart notes specifying type, duration, and frequency of activity
    • Physical Activity — recurring receipts for gym membership plus notes specifying type/duration/frequency
    • Physical Activity — summary report from a wearable device showing frequency (for example, elevated HR >20 minutes at least 3x/week for a month)
    • Physical Activity — recurring appointments with a personal trainer with notes specifying type/duration/frequency
    • Please attach chart notes to document weight-related comorbidities, prediabetes/type 2 diabetes, cardiovascular disease, and sleep study reports where applicable
    Documentation Required

    Previous therapy documentation

    Provide prior therapy information for any previous weight-loss medications tried (examples: Contrave, Wegovy, Qsymia, Xenical, Saxenda, prior Zepbound), including dates of therapy and reason for discontinuation or failure. For members currently on a weight-loss medication, document the medication name, duration on therapy, and on-therapy height/weight/BMI. Include baseline (pre-therapy) height, weight, and BMI with supporting chart documentation.

    • List previous weight-loss medications with dates of therapy and outcomes/failure reasons
    • If currently on therapy: name of medication and duration on therapy
    • Provide baseline (before any current weight-loss medication) height, weight, and BMI with documentation
    • Provide current (on-therapy) height, weight, and BMI if member is presently on a weight-loss medication
    • Attach chart notes or other clinical documentation to support all dates, measures, and medication trials
    Denial Risk

    Submission and payment risk

    Incomplete forms or missing supporting documentation may result in denial of the request. Payment is subject to member eligibility, benefit limits, and receipt of any required prior authorization. Ensure all requested documentation (clinical notes, lab tests, device reports, receipts, and program summaries) is included to avoid delays or adverse payment decisions.

    • Incomplete forms or missing documentation may lead to denial
    • Payment is subject to eligibility, benefit limits, and prior authorization requirements
    • Include clinical notes, lab reports (eg, A1c, FPG, OGTT where relevant), sleep study/device reports, and proof of program participation to support the request